Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to -$77000.0.

  • Akebia Therapeutics' Cash from Investing Activities fell 375000.0% to -$77000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$51000.0, marking a year-over-year decrease of 6451.61%. This contributed to the annual value of -$33000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Akebia Therapeutics reported Cash from Investing Activities of -$77000.0 as of Q3 2025, which was down 375000.0% from -$126000.0 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Cash from Investing Activities registered a high of $20.0 million during Q2 2021, and its lowest value of -$126000.0 during Q2 2025.
  • In the last 4 years, Akebia Therapeutics' Cash from Investing Activities had a median value of -$2000.0 in 2024 and averaged $4.4 million.
  • In the last 5 years, Akebia Therapeutics' Cash from Investing Activities surged by 803918.37% in 2021 and then tumbled by 375000.0% in 2025.
  • Over the past 4 years, Akebia Therapeutics' Cash from Investing Activities (Quarter) stood at $20.0 million in 2021, then plummeted by 100.57% to -$114000.0 in 2022, then soared by 98.25% to -$2000.0 in 2024, then tumbled by 3750.0% to -$77000.0 in 2025.
  • Its Cash from Investing Activities stands at -$77000.0 for Q3 2025, versus -$126000.0 for Q2 2025 and $154000.0 for Q1 2025.